EG1206A
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EG1206A, covering 2025-10-14 to 2025-10-14. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. [Phase 3]